Aquatic Capital Management LLC Has $10.99 Million Stake in Insmed, Inc. $INSM

Aquatic Capital Management LLC trimmed its stake in Insmed, Inc. (NASDAQ:INSM) by 61.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 76,343 shares of the biopharmaceutical company’s stock after selling 123,591 shares during the quarter. Aquatic Capital Management LLC’s holdings in Insmed were worth $10,994,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in Insmed by 13.0% in the 3rd quarter. Vanguard Group Inc. now owns 19,935,820 shares of the biopharmaceutical company’s stock worth $2,870,957,000 after buying an additional 2,291,328 shares in the last quarter. Capital International Investors grew its holdings in shares of Insmed by 1.0% during the 3rd quarter. Capital International Investors now owns 7,553,853 shares of the biopharmaceutical company’s stock valued at $1,087,830,000 after acquiring an additional 74,994 shares in the last quarter. Artisan Partners Limited Partnership grew its holdings in shares of Insmed by 49.0% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company’s stock valued at $711,076,000 after acquiring an additional 1,623,342 shares in the last quarter. Duquesne Family Office LLC increased its stake in shares of Insmed by 3.0% in the third quarter. Duquesne Family Office LLC now owns 2,423,435 shares of the biopharmaceutical company’s stock worth $348,999,000 after acquiring an additional 70,000 shares during the last quarter. Finally, Invesco Ltd. increased its stake in shares of Insmed by 5.7% in the third quarter. Invesco Ltd. now owns 2,003,871 shares of the biopharmaceutical company’s stock worth $288,577,000 after acquiring an additional 107,538 shares during the last quarter.

Insmed Trading Down 0.0%

Shares of NASDAQ:INSM opened at $139.50 on Monday. The stock has a market capitalization of $30.07 billion, a PE ratio of -21.76 and a beta of 1.13. Insmed, Inc. has a 1 year low of $60.40 and a 1 year high of $212.75. The firm has a fifty day moving average price of $155.18 and a 200 day moving average price of $166.16. The company has a current ratio of 3.83, a quick ratio of 3.54 and a debt-to-equity ratio of 0.76.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. During the same period in the previous year, the company earned ($1.32) earnings per share. The company’s quarterly revenue was up 152.6% compared to the same quarter last year. Analysts expect that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 19,215 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $169.00, for a total value of $3,247,335.00. Following the transaction, the chief executive officer directly owned 306,891 shares of the company’s stock, valued at approximately $51,864,579. This trade represents a 5.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the completion of the transaction, the insider directly owned 41,754 shares in the company, valued at $7,315,300.80. The trade was a 67.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 189,651 shares of company stock worth $31,784,545. 3.00% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

INSM has been the subject of a number of research reports. TD Cowen set a $241.00 price objective on Insmed in a research report on Thursday, December 18th. Truist Financial set a $205.00 target price on Insmed in a research report on Monday, January 12th. Cantor Fitzgerald raised their price target on Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a report on Thursday, January 22nd. Finally, Mizuho lowered their price target on Insmed from $211.00 to $204.00 and set an “outperform” rating for the company in a research note on Tuesday, February 24th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $207.52.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.